{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:53:35Z","timestamp":1791305615018,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are limited data to guide antiseizure medication (ASM) prophylaxis in patients with aneurysmal subarachnoid hemorrhage (SAH). This results in practice variation in the use and duration of ASM prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of articles assessing ASM prophylaxis in adults with aneurysmal SAH. The population, intervention, comparator, and outcome (PICO) questions were as follows: (1) Should ASM or no ASM be used in patients hospitalized for aneurysmal subarachnoid hemorrhage who have no history of clinical or electrographic seizures? (2) If an ASM is used, should levetiracetam or phenytoin\/fosphenytoin be preferentially used? (3) If an ASM is used, should a long (&gt;\u20093\u00a0days) or short (\u2264\u20093\u00a0days) duration of prophylaxis be used? The main outcomes were early seizure (\u2264\u200914\u00a0days), late seizures (&gt;\u200914\u00a0days), adverse events, mortality, and functional outcomes. We used Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to generate recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The initial literature search yielded 1988 articles, of which 10 formed the basis of the recommendations: Regarding PICO 1, we did not find a significant difference in outcomes of early seizure, adverse events, mortality, or functional outcomes when comparing ASM to no ASM. In regard to PICO 2, we found fewer early seizures with phenytoin\/fosphenytoin and lower risk for neurologic decline with levetiracetam; however, there was low certainty of evidence. There was no significant difference in mortality between the different treatment types. Regarding PICO 3, we found extended use of ASM may be associated with lower seizure risk, but at the same time be associated with higher risk for adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, the quality of evidence is low, precluding strong recommendations. We suggest that ASM or no ASM may be used in patients hospitalized with aneurysmal subarachnoid hemorrhage (conditional recommendation, low quality of evidence). If used, we suggest either levetiracetam or phenytoin\/fosphenytoin (conditional recommendation, very low quality of evidence) for a short or long duration (conditional recommendation, moderate quality of evidence).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-026-02614-z","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:14:50Z","timestamp":1785870890000},"page":"445-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guidelines for Seizure Prophylaxis in Patients with Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-9233","authenticated-orcid":false,"given":"A. Shaun","family":"Rowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar F.","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eljim","family":"Tesoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaiWai","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appaji","family":"Rayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Frontera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"5","key":"2614_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/00006123-200211000-00006","volume":"51","author":"LJ Dennis","year":"2002","unstructured":"Dennis LJ, Claassen J, Hirsch LJ, et al. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1136.","journal-title":"Neurosurgery"},{"issue":"6","key":"2614_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1017\/cjn.2017.206","volume":"44","author":"SH Mahmoud","year":"2017","unstructured":"Mahmoud SH, Buxton J. Seizures and choice of antiepileptic drugs following subarachnoid hemorrhage: a review. Can J Neurol Sci. 2017;44(6):643.","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"2614_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3340\/jkns.2009.46.2.93","volume":"46","author":"KS Choi","year":"2009","unstructured":"Choi KS, Chun HJ, Yi HJ, et al. Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. J Korean Neurosurg Soc. 2009;46(2):93\u20138.","journal-title":"J Korean Neurosurg Soc"},{"issue":"2","key":"2614_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.55.2.258","volume":"55","author":"DH Rhoney","year":"2000","unstructured":"Rhoney DH, Tipps LB, Murry KR, et al. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2000;55(2):258\u201365.","journal-title":"Neurology"},{"issue":"3","key":"2614_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000002281","volume":"86","author":"GM De Marchis","year":"2016","unstructured":"De Marchis GM, Pugin D, Meyers E, et al. Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome. Neurology. 2016;86(3):253\u201360.","journal-title":"Neurology"},{"issue":"2","key":"2614_CR6","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2009.46.2.93","volume":"46","author":"K-S Choi","year":"2009","unstructured":"Choi K-S, Chun H-J, Yi H-J, et al. Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. J Korean Neurosurg Soc. 2009;46(2):93.","journal-title":"J Korean Neurosurg Soc"},{"issue":"6","key":"2614_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuros\/nyx334","volume":"82","author":"BNR Jaja","year":"2018","unstructured":"Jaja BNR, Schweizer TA, Claassen J, et al. The SAFARI score to assess the risk of convulsive seizure during admission for aneurysmal subarachnoid hemorrhage. Neurosurgery. 2018;82(6):887.","journal-title":"Neurosurgery"},{"key":"2614_CR8","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/j.wneu.2024.01.146","volume":"184","author":"VT Le","year":"2024","unstructured":"Le VT, Nguyen AM, Nguyen PL. Risk factors for in-hospital seizure and new-onset epilepsy in coiling and clipping treatment of aneurysmal subarachnoid hemorrhage. World Neurosurg. 2024;184:e460\u20137.","journal-title":"World Neurosurg"},{"issue":"7","key":"2614_CR9","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2023;54(7):e314\u201370.","journal-title":"Stroke"},{"key":"2614_CR10","doi-asserted-by":"crossref","unstructured":"Huttunen, J.M., Kurki, M.I., von und zu Fraunberg, M., et al. Epilepsy after aneurysmal subarachnoid hemorrhage: a population-based, long-term follow-up study. Neurology 2015;85(22):1997.","DOI":"10.1212\/01.wnl.0000475449.00027.3b"},{"issue":"7","key":"2614_CR11","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1161\/STROKEAHA.116.013766","volume":"47","author":"D Panczykowski","year":"2016","unstructured":"Panczykowski D, Pease M, Zhao Y, et al. Prophylactic antiepileptics and seizure incidence following subarachnoid hemorrhage: a propensity score-matched analysis. Stroke. 2016;47(7):1754.","journal-title":"Stroke"},{"issue":"6","key":"2614_CR12","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly Jr","year":"2012","unstructured":"Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2012;43(6):1711\u201337.","journal-title":"Stroke"},{"issue":"1","key":"2614_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-023-01713-5","volume":"39","author":"MM Treggiari","year":"2023","unstructured":"Treggiari MM, Rabinstein AA, Busl KM, et al. Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2023;39(1):1\u201328.","journal-title":"Neurocrit Care"},{"key":"2614_CR14","unstructured":"GRADE. cited 2022; available from: https:\/\/www.gradeworkinggroup.org\/."},{"key":"2614_CR15","unstructured":"Schunemann, H.J.B., J.; Guyatt, G.; Oxman, A. GRADE handbook. 2022; available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"2614_CR16","unstructured":"GRADE Guidelines Workshop + focus on implementation. cited 2022; available from: https:\/\/gradeconf.org\/2022-11\/."},{"issue":"4","key":"2614_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395\u2013400.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2614_CR18","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1136\/jnnp.2003.026856","volume":"75","author":"SJ Buczacki","year":"2004","unstructured":"Buczacki SJ, Kirkpatrick PJ, Seeley HM, Hutchinson PJ. Late epilepsy following open surgery for aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2004;75(11):1620.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2614_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jocn.2004.03.019","volume":"11","author":"C-W Chen","year":"2004","unstructured":"Chen C-W, Kuo J-R, Lin H-J, et al. Early post-operative seizures after burr-hole drainage for chronic subdural hematoma: correlation with brain CT findings. J Clin Neurosci. 2004;11(7):706\u20139.","journal-title":"J Clin Neurosci"},{"issue":"6","key":"2614_CR20","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1097\/MJT.0000000000000940","volume":"26","author":"P-C Lin","year":"2019","unstructured":"Lin P-C, Chen C-Y, Chu C-W, et al. Psychotic symptoms related to the prophylactic use of levetiracetam after brain surgery. Am J Ther. 2019;26(6):e767.","journal-title":"Am J Ther"},{"issue":"5-6","key":"2614_CR21","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.wneu.2012.08.006","volume":"79","author":"DMS Raper","year":"2013","unstructured":"Raper DMS, Starke RM, Komotar RJ, Allan R, Connolly ES Jr. Seizures after aneurysmal subarachnoid hemorrhage: a systematic review of outcomes. World Neurosurg. 2013;79(5\u20136):682.","journal-title":"World Neurosurg"},{"issue":"2","key":"2614_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/01.WNL.0000038906.71394.DE","volume":"60","author":"J Claassen","year":"2003","unstructured":"Claassen J, Peery S, Kreiter KT, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology. 2003;60(2):208\u201314.","journal-title":"Neurology"},{"issue":"1","key":"2614_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-024-02183-z","volume":"42","author":"JA Frontera","year":"2025","unstructured":"Frontera JA, Rayi A, Tesoro E, et al. Guidelines for seizure prophylaxis in patients hospitalized with nontraumatic intracerebral hemorrhage: a clinical practice guideline for health care professionals from the neurocritical care society. Neurocrit Care. 2025;42(1):1\u201321.","journal-title":"Neurocrit Care"},{"key":"2614_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-023-01907-x","author":"JA Frontera","year":"2024","unstructured":"Frontera JA, Gilmore EJ, Johnson EL, et al. Guidelines for seizure prophylaxis in adults hospitalized with moderate-severe traumatic brain injury: a clinical practice guideline for health care professionals from the Neurocritical Care Society. Neurocrit Care. 2024. https:\/\/doi.org\/10.1007\/s12028-023-01907-x.","journal-title":"Neurocrit Care"},{"key":"2614_CR25","unstructured":"Higgins, J.P.S., J; Page, MJ; Elbers, RG; Sterne, JAC, Chapter 8: Assessing risk of bias in a randomized trial. In: Cochrane handbook for systematic reviews of interventions version 6.3, T.J. Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2022, Cochrane."},{"key":"2614_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J. 2016;355:i4919.","journal-title":"Br Med J"},{"issue":"4","key":"2614_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2614_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7461\/jcen.2015.17.3.166","volume":"17","author":"SJ Yoon","year":"2015","unstructured":"Yoon SJ, Joo JY, Kim YB, Hong CK, Chung J. Effects of prophylactic antiepileptic drugs on clinical outcomes in patients with a good clinical grade suffering from aneurysmal subarachnoid hemorrhage. J Cerebrovasc Endovasc Neurosurg. 2015;17(3):166\u201372.","journal-title":"J Cerebrovasc Endovasc Neurosurg"},{"issue":"2","key":"2614_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.wneu.2010.09.002","volume":"75","author":"T Murphy-Human","year":"2011","unstructured":"Murphy-Human T, Welch E, Zipfel G, Diringer MN, Dhar R. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. World Neurosurg. 2011;75(2):269\u201374.","journal-title":"World Neurosurg"},{"issue":"6","key":"2614_CR30","first-page":"1","volume":"9","author":"TV Kodankandath","year":"2017","unstructured":"Kodankandath TV, Farooq S, Wazni W, et al. Seizure prophylaxis in the immediate post-hemorrhagic period in patients with aneurysmal subarachnoid hemorrhage. J Vasc Interv Neurol. 2017;9(6):1\u20134.","journal-title":"J Vasc Interv Neurol"},{"issue":"10","key":"2614_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.seizure.2009.09.003","volume":"18","author":"D Shah","year":"2009","unstructured":"Shah D, Husain AM. Utility of levetiracetam in patients with subarachnoid hemorrhage. Seizure. 2009;18(10):676.","journal-title":"Seizure"},{"issue":"9","key":"2614_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jocn.2014.03.009","volume":"21","author":"RR Karamchandani","year":"2014","unstructured":"Karamchandani RR, Fletcher JJ, Pandey AS, Rajajee V. Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2014;21(9):1507\u201313.","journal-title":"J Clin Neurosci"},{"issue":"5","key":"2614_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40262-020-00979-8","volume":"60","author":"FB Sime","year":"2021","unstructured":"Sime FB, Roberts JA, Jeffree RL, et al. Population pharmacokinetics of levetiracetam in patients with traumatic brain injury and subarachnoid hemorrhage exhibiting augmented renal clearance. Clin Pharmacokinet. 2021;60(5):655\u201364.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2614_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12028-017-0440-5","volume":"28","author":"T Human","year":"2018","unstructured":"Human T, Diringer MN, Allen M, et al. A randomized trial of brief versus extended seizure prophylaxis after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2018;28(2):169\u201374.","journal-title":"Neurocrit Care"},{"key":"2614_CR35","doi-asserted-by":"crossref","unstructured":"Chumnanvej, S., Dunn, I.F., Kim, D.H. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery 2007;60(1):99\u2013102; discussion \u20133.","DOI":"10.1227\/01.NEU.0000249207.66225.D9"},{"issue":"3","key":"2614_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/01.STR.0000141936.36596.1e","volume":"36","author":"AM Naidech","year":"2005","unstructured":"Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583\u20137.","journal-title":"Stroke"},{"issue":"1","key":"2614_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNP.0000000000000806","volume":"38","author":"LJ Hirsch","year":"2021","unstructured":"Hirsch LJ, Fong MWK, Leitinger M, et al. American Clinical Neurophysiology Society\u2019s standardized critical care EEG terminology: 2021 version. J Clin Neurophysiol. 2021;38(1):1\u201329.","journal-title":"J Clin Neurophysiol"},{"issue":"4","key":"2614_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaneurol.2019.4656","volume":"77","author":"AF Struck","year":"2020","unstructured":"Struck AF, Tabaeizadeh M, Schmitt SE, et al. Assessment of the validity of the 2HELPS2B score for inpatient seizure risk prediction. JAMA Neurol. 2020;77(4):500\u20137.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2614_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12028-015-0127-8","volume":"23","author":"CC May","year":"2015","unstructured":"May CC, Arora S, Parli SE, et al. Augmented renal clearance in patients with subarachnoid hemorrhage. Neurocrit Care. 2015;23(3):374\u20139.","journal-title":"Neurocrit Care"},{"issue":"10","key":"2614_CR40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/02699052.2023.2184495","volume":"37","author":"A Hedges","year":"2023","unstructured":"Hedges A, Findlay MC, Davis GE, et al. Levetiracetam dosing for seizure prophylaxis in neurocritical care patients. Brain Inj. 2023;37(10):1167\u201372.","journal-title":"Brain Inj"},{"issue":"3","key":"2614_CR41","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s12028-025-02347-5","volume":"43","author":"M Kharouba","year":"2025","unstructured":"Kharouba M, Cook AM, Bastin MLT, Kutsogiannis DJ, Mahmoud SH. Levetiracetam dosing optimization in neurocritical care population: neuro-ARC study. Neurocrit Care. 2025;43(3):887\u2013901.","journal-title":"Neurocrit Care"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02614-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-026-02614-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02614-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:10:09Z","timestamp":1791303009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-026-02614-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2614"],"URL":"https:\/\/doi.org\/10.1007\/s12028-026-02614-z","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No authors have potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"No generative artificial intelligence tools were used in the writing of this manuscript.","order":2,"name":"Ethics","label":"Artificial Intelligence","group":{"name":"EthicsHeading","label":"Ethics"}}]}}